Hong Fang Song Sells 700,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Hong Fang Song sold 700,000 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $28.00, for a total value of $19,600,000.00. Following the completion of the sale, the director now owns 3,003,931 shares in the company, valued at approximately $84,110,068. The trade was a 18.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

CG Oncology Stock Performance

Shares of CGON stock traded up $0.06 on Tuesday, hitting $29.27. The company had a trading volume of 1,745,797 shares, compared to its average volume of 661,869. CG Oncology, Inc. has a twelve month low of $25.77 and a twelve month high of $50.23. The company has a 50-day moving average price of $35.10 and a 200-day moving average price of $34.88.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. On average, equities analysts expect that CG Oncology, Inc. will post -1.32 EPS for the current year.

Institutional Trading of CG Oncology

A number of hedge funds have recently added to or reduced their stakes in the company. State Street Corp raised its position in shares of CG Oncology by 73.0% in the third quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after acquiring an additional 717,722 shares during the period. Yu Fan purchased a new position in CG Oncology during the second quarter worth approximately $49,828,000. Janus Henderson Group PLC grew its holdings in CG Oncology by 7.0% in the third quarter. Janus Henderson Group PLC now owns 1,526,534 shares of the company's stock valued at $57,596,000 after purchasing an additional 99,517 shares during the period. Franklin Resources Inc. increased its position in shares of CG Oncology by 8.9% in the third quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company's stock valued at $46,157,000 after buying an additional 100,106 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of CG Oncology by 96.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after buying an additional 528,749 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CGON has been the topic of a number of recent analyst reports. UBS Group assumed coverage on CG Oncology in a research note on Thursday, October 24th. They issued a "buy" rating and a $60.00 target price on the stock. Roth Capital upgraded shares of CG Oncology to a "strong-buy" rating in a report on Tuesday, August 27th. Bank of America restated a "buy" rating and issued a $65.00 target price on shares of CG Oncology in a research note on Tuesday, October 8th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $63.88.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.